Harriet Kluger is a Cancer Immunotherapy and Biomarkers physician affiliated with Yale Cancer Center. OpenAlex indexes 842 publications with 32,554 citations (h-index 80); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 22 Oct 2026
Harriet Kluger, MD, is affiliated with Yale Cancer Center. The public record shows 842 publications with 32,554 citations (h-index 80), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 9 companies, 11 NIH-funded awards (2005–2026).
- Most recent indexed publication: 2026 · Cancer immunology research
- Top research focus: Cancer Immunotherapy and Biomarkers
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 277.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Yale University
- Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
Sponsor: Yale University
Industry payments
Updated 22 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Immunocore LimitedProgram year20252 payments
- Genmab U.S., Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20238 payments$13,131openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.2%Kinase inhibitor34.2%Lenvima48%Cabometyx32%Inlyta20%Part D<11 patientsMetabolism & gastrointestinal
34.2%Corticosteroid18.9%Prednisone100%Part D≥20 patientsSerotonin-3 Receptor Antagonist8.9%Ondansetron Odt100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
31.6%l-Thyroxine31.6%Levothyroxine Sodium100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
11 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAM
Yale University
FY2026$717,601K12CA215110 - Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapy
Yale University
FY2026$674,193R01CA269349
Congress activity
Updated 22 Oct 2026
103 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 3381: ImmunoPET reveals tumor-associated macrophages in humanized MDA-MB-231 models
AACR Annual Meeting
AACR2026Co-author - Abstract 4998: ImmunoPET imaging of human tumor associated macrophages
AACR Annual Meeting
AACR2026Co-author - Enrichment of the germline NLRC5 Pro191Leu variant in patients with immune checkpoint inhibitor–induced hepatitis.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 22 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phenotypic and functional characterization of tumor-reactive T cells in malignant pleural effusions.
Cancer immunology research
Article2026 - Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.
Journal for immunotherapy of cancer
Article2026 - Advances in Cancer Immunotherapy for Solid Tumors.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Review2026 - Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.
Cancer immunology research
Article2026
Most-cited works
by citation count (OpenAlex)- 01Nivolumab plus Ipilimumab in Advanced MelanomaArticle4,230 citations2013
- 02
- 03PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell CarcinomaArticle1,260 citations2016
- 04Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaArticle1,189 citations2012
- 05
Network
Updated 22 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
medicine.yale.edu/cancer/profile/harriet-kluger
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Other
medicine.yale.edu/profile/harriet-kluger
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Krop, MD
Yale Cancer Center
Stephanie Halene, MD
Yale Cancer Center
John Kunstman, MD
Yale Cancer Center
Michael Schilsky, MD
Yale Cancer Center
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Mario Sznol, MD
University of Miami Miller School of Medicine
Igor Puzanov, MD
Roswell Park Comprehensive Cancer Center